Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Average Rating of “Moderate Buy” by Analysts

Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) have received an average recommendation of “Moderate Buy” from the seven analysts that are covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $15.80.

Several analysts have issued reports on AMRX shares. Zacks Research lowered Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 6th. Barclays upped their target price on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 20th. Weiss Ratings lowered Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, May 26th. UBS Group began coverage on Amneal Pharmaceuticals in a research note on Friday, April 17th. They issued a “buy” rating and a $19.00 target price for the company. Finally, Wall Street Zen lowered Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 13th.

Amneal Pharmaceuticals Price Performance

Shares of AMRX opened at $16.28 on Thursday. The firm has a market cap of $5.19 billion, a P/E ratio of 42.84 and a beta of 1.30. The stock has a 50 day simple moving average of $13.26 and a two-hundred day simple moving average of $13.18. Amneal Pharmaceuticals has a 1 year low of $7.66 and a 1 year high of $16.61.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its earnings results on Thursday, May 7th. The company reported $0.27 earnings per share (EPS) for the quarter. The business had revenue of $722.52 million during the quarter. Amneal Pharmaceuticals had a negative return on equity of 313.96% and a net margin of 4.01%. On average, equities analysts anticipate that Amneal Pharmaceuticals will post 0.92 earnings per share for the current year.

Insider Buying and Selling at Amneal Pharmaceuticals

In other news, Director Deborah M. Autor sold 34,819 shares of the stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $12.94, for a total transaction of $450,557.86. Following the completion of the sale, the director owned 93,660 shares of the company’s stock, valued at approximately $1,211,960.40. This represents a 27.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 17.30% of the company’s stock.

Institutional Trading of Amneal Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. Spire Wealth Management boosted its stake in shares of Amneal Pharmaceuticals by 66.6% during the fourth quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock valued at $32,000 after purchasing an additional 1,023 shares during the period. Intech Investment Management LLC boosted its stake in shares of Amneal Pharmaceuticals by 1.2% during the fourth quarter. Intech Investment Management LLC now owns 97,573 shares of the company’s stock valued at $1,229,000 after purchasing an additional 1,159 shares during the period. Hsbc Holdings PLC boosted its stake in shares of Amneal Pharmaceuticals by 1.6% during the fourth quarter. Hsbc Holdings PLC now owns 101,945 shares of the company’s stock valued at $1,297,000 after purchasing an additional 1,569 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Amneal Pharmaceuticals by 2.4% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 68,137 shares of the company’s stock valued at $859,000 after purchasing an additional 1,582 shares during the period. Finally, Comerica Bank boosted its stake in shares of Amneal Pharmaceuticals by 56.1% during the fourth quarter. Comerica Bank now owns 4,690 shares of the company’s stock valued at $59,000 after purchasing an additional 1,685 shares during the period. Hedge funds and other institutional investors own 31.82% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.